Acido piruvico- ficha tecnica

Prévia do material em texto

Estudos 
http://aformulabr.com.br/qrcode/acidopiruvicoafv01.pdf 
 
 
 
 
 
 
 
ÁCIDO PIRÚVICO 
 
Opção no peeling 
 
 
DESCRIÇÃO 
 
O ácido pirúvico é um alfacetoácido que é convertido na pele, sob condições fisiológicas em ácido láctico, pela ação 
da enzima lactato desidrogenase. É considerado um potente agente usado no peeling químico por possuir rápida e 
fácil penetração, além de ser um dos umectantes naturais mais eficazes para a pele. 
 
MECANISMO DE AÇÃO 
 
O ácido pirúvico como potente agente para peeling químico, em altas concentrações possui rápida e profunda 
penetração na pele, que ocasiona estímulo na derme referente a biossíntese de glicosaminoglicanos, colágeno e 
fibras elásticas. O ácido pirúvico além disso, promove a renovação dos queratinócitos por ativar receptores 
específicos na epiderme que estimulam a diferenciação dos queratinócitos, mantendo a homeostasia da barreira 
cutânea e impulsionando a proliferação dérmica. Em baixas concentrações, apresenta um efeito plastificante e 
hidratante do estrato córneo causados por suas propriedades umectantes. Ademais, apresenta ação antimicrobiana e 
propriedades sebostática. 
 
INDICAÇÕES 
 
 Fotodano moderado; hiperpigmentação (pós-inflamatória e pós actínica, melasma, etc.); 
 Acne inflamatória, acne ativa, rosácea, cicatriz, dermatite, queratose, verrugas, etc.; 
 Rugas finas e queloides. 
 
DOSE USUAL 
 
Recomendação tópica de 40 a 70% em água ou etanol (peeling superficial a médio) de ácido pirúvico - uso em 
consultório. 
 
SUGESTÕES DE FÓRMULAS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PRINCIPAIS REFERÊNCIAS 
 
COSTA, Adilson. Tratado Internacional de Cosmecêutico. Rio de Janeiro: Guanabara Koogan, 2012. 
 
NARDIN, P.; GUTERRES, S.S. Alfa-hidroxiácidos: aplicações cosméticas e dermatológicas. Caderno de Farmácia v. 15, n. 1, p.7-14, 1999. 
Disponível em:< http://www.lume.ufrgs.br/bitstream/handle/10183/19373/000296082.pdf?sequence=1>. Acesso em: 12/01/2017. 
 
 
Ácido pirúvico ..................................................... 50% 
Etanol qsp............................................................. 30ml 
 
+ 
 
Peeling de Ácido salicílico 30% qsp ................... 30ml 
 
Modo de uso: aplicar sobre a face após higienização. 
5 camadas por vez, em intervalos de 2 semanas. 
Indicação: diminuição do nível de sebo. 
 
Ácido pirúvico .................................................... 50 % 
Propilenoglicol........................................................ 5 % 
Etanol qsp............................................................ 30 ml 
 
 
Modo de uso: aplicar sobre a face após a 
higienização. Deixar agir de 1 a 3 minutos 
Indicação: peeling de ácido pirúvico. 
 
 
 
 
ÁCIDO PIRÚVICO 
 
ESTUDOS CLÍNICOS 
 
 
Comparative study of the effect of 50% pyruvic and 30% salicylic peels on the skin lipid film in patients with 
acne vulgaris. 
 
Pyruvic (alfa-keto acid) and salicylic (beta-hydroxy acid) acids are superficial peels frequently used in patients with 
acne vulgaris. AIM: The aim of the study was to compare the effect of 50% pyruvic and 30% salicylic peels on facial 
sebum secretion in patients with acne vulgaris, aged 13-30. MATERIAL AND METHODS: The level of secreted 
sebum was determined in 20 men and women. Ten patients were treated with 50% pyruvic acid and the remaining 10 
with 30% salicylic acid. Each peel was applied five times at 2-week intervals. The sebum measurements were taken in 
the T- and U-zones using a Sebumeter SM 815 (Courage & Khazaka, Germany). The last, sixth measurement was 
taken 2 weeks after the treatment. RESULTS: A statistically significant decrease in the level of secreted sebum in both 
U- and T- zones was observed in the patients studied after the third application of 50% pyruvic peel and the second 
application of 30% salicylic peel. Two weeks following the completion of therapy, sebumetric measurements 
demonstrated a greater reduction in the facial skin lipid film among the patients treated with salicylic peel. 
CONCLUSIONS: Peels with 50% pyruvic acid and 30% salicylic acid are the procedures that significantly contributed 
to a decrease in the level of secreted sebum on the facial skin surface in the group of patients studied. A greater 
therapeutic effect was observed following 30% salicylic peel, which might be associated with its high lipophilic 
properties and easier penetration through the lipid barriers of the epidermis. 
 
 
 
Clinical and instrumental evaluation of skin improvement after treatment with a new 50% pyruvic acid peel. 
 
OBJECTIVE: The aim of the study is to assess the efficacy and tolerability of 50% pyruvic acid in a new non-
erythematogenic formulation (pyruvic acid 50%, dimethyl isosorbide, propylene glycol, ethyl alcohol, dimethyl sulfone, 
ethyl lactate, water) for the treatment of photodamage, superficial scarring, and melasma. MATERIALS AND 
METHODS: Twenty subjects affected by photodamage, superficial scarring, and melasma, but otherwise healthy, 
entered the study. Four peeling sessions were performed once every 2 weeks. The patients were evaluated clinically 
and by means of several noninvasive methods in order to monitor the following parameters: hydration, color (erythema 
and pigmentation), elasticity, skin smoothness, skin roughness, scaliness, and wrinkles. CONCLUSION: This 
innovative formulation of 50% pyruvic acid peel has been shown to be safe and effective to treat photodamage, 
melasma, and superficial scarring, allowing the patients to carry out regularly their working life as well as their social 
life. Furthermore, the results have been evaluated by means of noninvasive devices, which have permitted one to 
quantify the improvements. 
 
 
 
Comparative study of the effect of 50% pyruvic and 30% salicylic peels on the skin lipid film in patients 
withacne vulgaris 
 
Pyruvic (alfa-keto acid) and salicylic (beta-hydroxy acid) acids are superficial peels frequently used in patients 
with acne vulgaris. AIM: The aim of the study was to compare the effect of 50% pyruvic and 30% salicylic peels on 
facial sebum secretion in patients with acne vulgaris, aged 13-30. MATERIAL AND METHODS: The level of secreted 
sebum was determined in 20 men and women. Ten patients were treated with 50% pyruvic acid and the remaining 10 
with 30% salicylic acid. Each peel was applied five times at 2-week intervals. The sebum measurements were taken in 
the T- and U-zones using a Sebumeter SM 815 (Courage & Khazaka, Germany). The last, sixth measurement was 
taken 2 weeks after the treatment. CONCLUSIONS: Peels with 50% pyruvic acid and 30% salicylic acid are the 
procedures that significantly contributed to a decrease in the level of secreted sebum on the facial skin surface in the 
group of patients studied. A greater therapeutic effect was observed following 30% salicylic peel, which might be 
associated with its high lipophilic properties and easier penetration through the lipid barriers of the epidermis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pyruvic acid peels for the treatment of photoaging. 
 
OBJECTIVE: The aim of our study was to evaluate the efficacy and tolerability of 50% pyruvic acid on moderately 
photodamaged facial skin. METHODS: We treated 20 patients with four peeling sessions at 4-week intervals. We 
evaluated the patients clinically, and in order to obtain an objective assessment of the effect of pyruvic acid on 
pigmentary components of the skin, erythema and hyperpigmentation response were measured in all the patients 
before and after treatment using a Minolta Tri-Stimulus Colorimeter II. RESULTS: The clinical evaluation of the 
patients after the peeling sessions demonstrated a smoother texture, less evident fine wrinkles, and evident lightening 
of hyperpigmentations (freckles and lentigines). In fact, chemical peels cause a thinning of the epidermis and a 
thickening of the dermis. The patients treated reported very limited or no discomfort in the postpeel period. 
CONCLUSION:Thus, 50% pyruvic acid peeling can be proposed as a safe and efficient treatment for moderate facial 
skin aging. 
 
 
 
Treatment of warts with topical pyruvic acid: with and without added 5-fluorouracil. 
 
Pyruvic acid (PA) is an alpha-hydroxy acid with potent keratolytic properties. Fifty-six patients with common warts 
treated with two PA formulations were surveyed 2 to 29 months after beginning treatment (mean, 18 months). Thirty-
eight patients used a 70 percent PA formulation with added 0.5 percent 5-fluorouracil (PA-5FU). Eighteen patients 
used a plain 70 percent PA formulation without added 5FU. Three-quarters of the patients reported using the 
formulation for 4 weeks or less. Overall, 64 percent of the patients treated with either of the two formulations 
experienced complete clearing of their lesions. There was no increased efficacy noted with the PA-5FU formulation. 
Eighty-two percent of eighteen children, aged 16 years or younger, experienced clearing of lesions. 
 
 
 
The use of pyruvic acid in the treatment of acne. 
 
OBJECTIVE: To evaluate the efficacy and tolerability of chemical peeling with pyruvic acid for treatment of mild to 
moderate papulo-pustular acne. METHODS: We conducted an open-label study in which patients affected by mild to 
moderate papulo-pustular acne were treated with 40-50% pyruvic acid every 2 weeks for a total of 3-4 months. Forty 
patients (26 women and 14 men), ranging in age from 18 to 30 years, were enrolled in the study. Evaluations of 
sebum production and skin hydration were performed before and after treatment in 24 patients. RESULTS: Complete 
remission was observed in 16 patients (40%), partial remission was detected in 20 patients (50%), and no 
improvement was seen in four patients (10%). No side-effects were observed during or after treatment. Post-treatment 
evaluation of sebum production in 24 patients revealed a reduction in sebum levels in all patients. Post-treatment 
values of cutaneous hydration did not vary significantly from pretreatment values in the 24 patients evaluated. 
CONCLUSIONS: The results of our study indicate that peeling with pyruvic acid can be considered an effective, safe 
and well-tolerated procedure in the treatment of patients affected by mild to moderate papulo-pustular acne. 
 
REFERÊNCIAS 
 
MARCZYK B.; MUCHA P.; BUDZISZ E.; ROTSZTEJN H. Comparative study of the effect of 50% pyruvic and 30% salicylic peels on the skin lipid 
film in patients with acne vulgaris. J Cosmet Dermatol. V.13, nº1, p.15-21. Mar; 2014. Disponível em:< 
http://www.ncbi.nlm.nih.gov/pubmed/24641601>. Acesso em: 25 de Julho de 2016, às 10:51. 
 
BERARDESCA E.; CAMELI N.; PRIMAVERA G.; CARRERA M. Clinical and instrumental evaluation of skin improvement after treatment with a new 
50% pyruvic acid peel. Dermatol Surg. V.32, nº4, p.526-31. Apr; 2006. Disponível em:< http://www.ncbi.nlm.nih.gov/pubmed/16681660>. Acesso 
em: 13 de Julho de 2016, às 15:16. 
 
MARCZYK B.; MUCHA P.; BUDZISZ E.; ROTSZTEJN H. Comparative study of the effect of 50% pyruvic and 30% salicylic peels on the skin lipid 
film in patients withacne vulgaris. J Cosmet Dermatol. V.13, nº1, p.15-21. Mar; 2014. Disponível em:< 
http://www.ncbi.nlm.nih.gov/pubmed/24641601>. Acesso em: 13 de Julho de 2016, às 15:09. 
 
GHERSETICH I.; BRAZZINI B.; PERIS K.; COTELLESSA C.; MANUNTA T.; LOTTI T. Pyruvic acid peels for the treatment of photoaging. Dermatol 
Surg. V.30, nº1, p.32-6. Jan; 2004. Disponível em:< http://www.ncbi.nlm.nih.gov/pubmed/14692923>. Acesso em: 13 de Julho de 2016, às 15:24. 
 
HALASZ C.L. Treatment of warts with topical pyruvic acid: with and without added 5-fluorouracil. Cutis. V.;62, nº6, p.283-5. Dec; 1998. Disponível 
em:< http://www.ncbi.nlm.nih.gov/pubmed/9878984>. Acesso em: 13 de Julho de 2016, às 14:44. 
 
COTELLESSA C.; MANUNTA T.; GHERSETICH I.; BRAZZINI B.; PERIS K. The use of pyruvic acid in the treatment of acne. J Eur Acad Dermatol 
Venereol. V.18, n°3, p.275-8. May; 2004. Disponível em:< http://www.ncbi.nlm.nih.gov/pubmed/15096135>. Acesso em: 25 de Julho de 2016. 
http://www.ncbi.nlm.nih.gov/pubmed/?term=Marczyk%20B%5BAuthor%5D&cauthor=true&cauthor_uid=24641601
http://www.ncbi.nlm.nih.gov/pubmed/?term=Mucha%20P%5BAuthor%5D&cauthor=true&cauthor_uid=24641601
http://www.ncbi.nlm.nih.gov/pubmed/?term=Budzisz%20E%5BAuthor%5D&cauthor=true&cauthor_uid=24641601
http://www.ncbi.nlm.nih.gov/pubmed/?term=Rotsztejn%20H%5BAuthor%5D&cauthor=true&cauthor_uid=24641601
http://www.ncbi.nlm.nih.gov/pubmed/24641601
http://www.ncbi.nlm.nih.gov/pubmed/?term=Berardesca%20E%5BAuthor%5D&cauthor=true&cauthor_uid=16681660
http://www.ncbi.nlm.nih.gov/pubmed/?term=Cameli%20N%5BAuthor%5D&cauthor=true&cauthor_uid=16681660
http://www.ncbi.nlm.nih.gov/pubmed/?term=Primavera%20G%5BAuthor%5D&cauthor=true&cauthor_uid=16681660
http://www.ncbi.nlm.nih.gov/pubmed/?term=Carrera%20M%5BAuthor%5D&cauthor=true&cauthor_uid=16681660
http://www.ncbi.nlm.nih.gov/pubmed/16681660
http://www.ncbi.nlm.nih.gov/pubmed/?term=Marczyk%20B%5BAuthor%5D&cauthor=true&cauthor_uid=24641601
http://www.ncbi.nlm.nih.gov/pubmed/?term=Mucha%20P%5BAuthor%5D&cauthor=true&cauthor_uid=24641601
http://www.ncbi.nlm.nih.gov/pubmed/?term=Budzisz%20E%5BAuthor%5D&cauthor=true&cauthor_uid=24641601
http://www.ncbi.nlm.nih.gov/pubmed/?term=Rotsztejn%20H%5BAuthor%5D&cauthor=true&cauthor_uid=24641601
http://www.ncbi.nlm.nih.gov/pubmed/24641601
http://www.ncbi.nlm.nih.gov/pubmed/?term=Ghersetich%20I%5BAuthor%5D&cauthor=true&cauthor_uid=14692923
http://www.ncbi.nlm.nih.gov/pubmed/?term=Brazzini%20B%5BAuthor%5D&cauthor=true&cauthor_uid=14692923
http://www.ncbi.nlm.nih.gov/pubmed/?term=Peris%20K%5BAuthor%5D&cauthor=true&cauthor_uid=14692923
http://www.ncbi.nlm.nih.gov/pubmed/?term=Cotellessa%20C%5BAuthor%5D&cauthor=true&cauthor_uid=14692923
http://www.ncbi.nlm.nih.gov/pubmed/?term=Manunta%20T%5BAuthor%5D&cauthor=true&cauthor_uid=14692923
http://www.ncbi.nlm.nih.gov/pubmed/?term=Lotti%20T%5BAuthor%5D&cauthor=true&cauthor_uid=14692923
http://www.ncbi.nlm.nih.gov/pubmed/14692923
http://www.ncbi.nlm.nih.gov/pubmed/14692923
http://www.ncbi.nlm.nih.gov/pubmed/?term=Halasz%20CL%5BAuthor%5D&cauthor=true&cauthor_uid=9878984
http://www.ncbi.nlm.nih.gov/pubmed/9878984
http://www.ncbi.nlm.nih.gov/pubmed/?term=Cotellessa%20C%5BAuthor%5D&cauthor=true&cauthor_uid=15096135
http://www.ncbi.nlm.nih.gov/pubmed/?term=Manunta%20T%5BAuthor%5D&cauthor=true&cauthor_uid=15096135
http://www.ncbi.nlm.nih.gov/pubmed/?term=Ghersetich%20I%5BAuthor%5D&cauthor=true&cauthor_uid=15096135
http://www.ncbi.nlm.nih.gov/pubmed/?term=Brazzini%20B%5BAuthor%5D&cauthor=true&cauthor_uid=15096135
http://www.ncbi.nlm.nih.gov/pubmed/?term=Peris%20K%5BAuthor%5D&cauthor=true&cauthor_uid=15096135
http://www.ncbi.nlm.nih.gov/pubmed/15096135
http://www.ncbi.nlm.nih.gov/pubmed/15096135